Webinar

Sterility Assurance & Contamination Control: Lessons from FDA 483s and Warning Letters, 2021–2026

  • Date: Thursday December 10, 2026
  • Time: 12:00 pm – 1:30 pm (NY Time)
  • Instructor(s): Barry A. Friedman Ph.D
  • Webinar ID#: ECC-778
Webinar Details:

Sterility assurance is process-based, not test-based. FDA used those words in its November 2025 Warning Letter to Catalent Indiana, and the idea runs through this 90-minute webinar. The session uses five years of FDA Form 483 observations and Warning Letters (2021–2026) as a curriculum. Each requirement is paired with what investigators wrote at sterile manufacturing sites.

The program maps US and EU expectations side by side: 21 CFR Parts 210/211, FDA's 2004 Aseptic Processing Guidance, EU GMP Annex 1 (2022, effective 25 August 2023), and the relevant USP chapters. Enforcement data frame the agenda. 211.113(b) and 211.42 lead sterile-site 483 observations, and citations for inadequate investigations (211.192) rose 171% from 2023 to 2024. Drug-quality Warning Letters reached a five-year high of 105 in FY2024.

Primary takeaways

  • A passing test does not close a failed process.
  • The same eight failures recur.
  • The CCS is the site's argument that its product is sterile.
  • Design EM and APS to find problems, not to pass.
  • Most Warning Letters are decided by the investigation and the response.

Who should attend
The session is for professionals who design, run, oversee or inspect sterile drug manufacturing:

  • Quality Assurance and Quality Control leaders, quality unit heads, and batch release staff
  • Microbiology and sterility assurance specialists, including EM program owners and sterility testing labs
  • Manufacturing and aseptic operations managers, supervisors and line leads
  • Validation and engineering staff responsible for sterilization, depyrogenation, HVAC, cleanrooms and RABS or isolators
  • Regulatory affairs and compliance professionals preparing for inspections or drafting 483 responses
  • 503B outsourcing facilities and sterile compounding pharmacies working under the 2004 guidance and USP <797>
  • CMO and supplier oversight teams, component sterilizers, and single-use system suppliers
  • Senior management accountable for CCS management review and CAPA effectiveness

Fee:
$385 for one person
$700 2-5 people
$999 6-10 people

Register for ECC-778